Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803703 | 0.89 | ELANE (0.46) | ELANEARALDH1A1PPARGPPARD | |
| SCHEMBL8814733 | 0.76 | AR (0.46) | ELANEARPGRTAS2R8IGF1R | |
| SCHEMBL13039129 | 0.74 | IGF1R (0.67) | ALDH1A1TAS2R8IGF1R | |
| SCHEMBL19923441 | 0.73 | GRM4 (0.57) | ELANEARALDH1A1PGR | |
| SCHEMBL8030958 | 0.73 | ELANE (0.46) | ELANEARTAS2R8IGF1R | |
| SCHEMBL7784176 | 0.72 | AR (0.71) | ARPGR | |
| SCHEMBL4005049 | 0.71 | ELANE (0.42) | ELANEALDH1A1PGR | |
| SCHEMBL11654508 | 0.70 | PGR (0.58) | ELANEALDH1A1PGR | |
| SCHEMBL8023307 | 0.70 | TAS2R8 (0.47) | ELANETAS2R8IGF1R | |
| SCHEMBL6278686 | 0.69 | BCHE (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ELANE 1219/4885EGLN1 553/4885AR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.